A new strategy for brain tumour metabolomic analysis
Abstract
Introduction: Nowadays, diagnosis of brain tumours is mainly carried out via neuroimaging techniques. The most widespread methods for routine analysis include computer tomography and magnetic resonance imaging. While such methods are useful to localise tumours, they are unable to offer a conclusive diagnosis of the tumour type. A final diagnosis can only be made via a histological examination of tissue after tumour resection, or, in cases where the location of the tumour is not amenable to resection, after a biopsy of the tumour is carried out. Untargeted metabolite analysis is a relatively new approach to diagnostics, capable of establishing wide characterisation of endogenous metabolites of a given system, a method that can be applied to improve identification of tumour types via biomarker discovery. In this regard, sample collection and preparation can be said to be the most important step in metabolomic studies.
Material and methods: In the current study, a solid phase microextraction (SPME) protocol for metabolo-mics, which has been successfully applied towards metabolite analysis in various biological materials in the last few years, was optimised for brain tumour tissue metabolomic analysis. In the current study, the described approach was applied to human brain tumours. Aiming to incur minimal tissue damage, the probes used for sampling were of diameter ca. 0.2 mm. Aiming to optimise the method towards enhanced recovery of the extracted metabolites, various desorption solvents were tested in an optimisation study. The final protocol was used for analysis of a pilot cohort of patients with glioma and meningioma tumours. Results: The results showed that a protocol where chemical biopsy was performed directly from resected tumour with 7-mm-long coating SPME probe and desorption was done using 0.3 mL of a mixture of acetonitrile and water 80:20 v/v was superior to other tested protocols. The optimised method allowed for successful differentiation between the two types of brain tumours studied: meningioma and glioma. Despite the relatively small cohort group involved in the study, several compounds were tentatively identified as statistically significant metabolites responsible for this differentiation.
Conclusions: The presented preliminary data demonstrate a potential of the proposed method as a low invasive diagnostic tool for on-site analysis.
Keywords: brain tumoursolid phase microextractionmetabolomicsmass spectrometry
References
- Stupp R, Mason W, Bent Mv, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine. 2005; 352(10): 987–996.
- Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002; 61(3): 215–25; discussion 226.
- Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6): 803–820.
- Zhao H, Heimberger AB, Lu Z, et al. Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes. Oncotarget. 2016; 7(15): 20486–20495.
- Pandey R, Caflisch L, Lodi A, et al. Metabolomic signature of brain cancer. Mol Carcinog. 2017; 56(11): 2355–2371.
- Griffin JL, Kauppinen RA. A metabolomics perspective of human brain tumours. FEBS J. 2007; 274(5): 1132–1139.
- Lopez CJ, Nagornaya N, Parra NA, et al. Association of Radiomics and Metabolic Tumor Volumes in Radiation Treatment of Glioblastoma Multiforme. Int J Radiat Oncol Biol Phys. 2017; 97(3): 586–595.
- Santagata S, Eberlin LS, Norton I, et al. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proc Natl Acad Sci U S A. 2014; 111(30): 11121–11126.
- Bojko B, Gorynski K, Gomez-Rios GA, et al. Solid phase microextraction fills the gap in tissue sampling protocols. Anal Chim Acta. 2013; 803: 75–81.
- Cudjoe E, Bojko B, Togunde P, et al. In vivo solid-phase microextraction for tissue bioanalysis. Bioanalysis. 2012; 4(21): 2605–2619.
- Goryński K, Goryńska P, Górska A, et al. SPME as a promising tool in translational medicine and drug discovery: From bench to bedside. J Pharm Biomed Anal. 2016; 130: 55–67.
- Bojko B, Reyes-Garcés N, Bessonneau V, et al. Solid-phase microextraction in metabolomics. TrAC Trends in Analytical Chemistry. 2014; 61: 168–180.
- Reyes-Garcés N, Gionfriddo E, Gómez-Ríos GA, et al. Advances in Solid Phase Microextraction and Perspective on Future Directions. Anal Chem. 2018; 90(1): 302–360.
- Vuckovic D, Pawliszyn J. Systematic evaluation of solid-phase microextraction coatings for untargeted metabolomic profiling of biological fluids by liquid chromatography-mass spectrometry. Anal Chem. 2011; 83(6): 1944–1954.
- Bessonneau V, Bojko B, Pawliszyn J. Analysis of human saliva metabolome by direct immersion solid-phase microextraction LC and benchtop orbitrap MS. Bioanalysis. 2013; 5(7): 783–792.
- Bojko B, Pawliszyn J. In vivo and ex vivo SPME: a low invasive sampling and sample preparation tool in clinical bioanalysis. Bioanalysis. 2014; 6(9): 1227–1239.
- Want EJ, Masson P, Michopoulos F, et al. Global metabolic profiling of animal and human tissues via UPLC-MS. Nat Protoc. 2013; 8(1): 17–32.
- Risticevic S, Lord H, Górecki T, et al. Protocol for solid-phase microextraction method development. Nat Protoc. 2010; 5(1): 122–139.
- Soga T, Baran R, Suematsu M, et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J Biol Chem. 2006; 281(24): 16768–16776.